



Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials

Christoffer Polcwiartek, MD,^{a,b,c} Pia Behrndtz, RN, Diploma of Health,^a Ann Hass Andersen, RN,^a Marianne Bregendahl, RN,^a Helle Pedersen Hald, RN,^a and Svend Eggert Jensen, MD, PhD^{a,c} Aalborg, Denmark

Background Limited evidence is available on attitudes and considerations of ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) toward participation in randomized clinical trials (RCTs). Therefore, we investigated the ability of these patients to decide participation in RCTs.

Methods This was a questionnaire-based study. Over a 9-month period, we approached and invited 100 consecutive STEMI patients who were asked to participate in at least one RCT during primary PCI. Patients were asked to fill out self-administered questionnaires concerning demographic data as well as attitudes and considerations toward participation in RCTs.

Results Patients had a mean (SD) age of 61 (12) years, and most were male (82%). With a response rate of 96%, a total of 94% accepted participation in at least one RCT. Most patients (78%) reported to understand the information on participation in RCTs at an acceptable to satisfactory level, and 83% reported that they were given the possibility to ask additional questions during the decision-making process. Few patients (2%) reported that they felt pressured to participate. Most patients (83%) reported that they participated to help clinical research, and 85% of patients would be willing to participate in future RCTs. It did not seem that the total number of RCTs that patients participated in was of significant importance.

Conclusions Patients with STEMI undergoing primary PCI had positive attitudes and considerations toward participation in RCTs despite their acute medical condition and the emergency environment. The overall self-assessed ability of patients to make a decision about participation in RCTs was good. (Am Heart J 2019;208:21-7.)

Randomized controlled trials (RCTs) remain the gold standard by which studies of treatment are assessed, and owing to several RCTs within the field of ST-elevation myocardial infarction (STEMI) research, the dominant reperfusion strategy has been deemed primary percutaneous coronary intervention (PCI), which has both improved survival and life quality of patients.¹ However, with demanding challenges in clinical practice such as improving access to care, door-to-balloon time, and adherence to guideline treatment recommendations, RCTs need to be even more sufficient in terms of developing novel treatments and improving existing ones for managing STEMI patients undergoing primary PCI.² As such, RCTs require efficient

recruitment of adequately sized study populations being representative of contemporary clinical practice to be successful.³ However, patient recruitment remains a widespread challenge across RCTs, and controversy over especially informed consent in STEMI RCTs has existed for more than 30 years.⁴

Although it is standard practice to ask STEMI patients to consent to participation in RCTs, this activity poses an ethical pitfall due to the acute medical condition of patients, the emergency environment, and the fact that randomization must occur within minutes of arrival at the catheterization laboratory.⁴ Therefore, only limited time is remaining for oral and written information and for patients to consider participation in RCTs. In addition, the psychological distress including fear of dying, ongoing pain, and helplessness associated with STEMI may compromise the decision-making process of patients and consequently the fundamentals of securing informed consent.⁵ Currently, few studies have assessed attitudes and considerations of patients toward participation in RCTs during the acute phase of STEMI and primary PCI; thus, deeper insight into this issue is warranted. Most of the focus in the literature has been on the experience of STEMI patients with the informed consent process in

From the ^aDepartment of Cardiology, Aalborg University Hospital, Aalborg, Denmark,

^bUnit of Epidemiology and Biostatistics, Aalborg University Hospital, Aalborg, Denmark, and ^cDepartment of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Conflicts of interest: All authors have no conflicts of interest in relation to the present topic. Submitted April 23, 2018; accepted October 20, 2018.

Reprint requests: Christoffer Polcwiartek, MD, Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, DK-9000 Aalborg, Denmark.

E-mail: c.polcwiartek@gmail.com

0002-8703

© 2018 Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.ahj.2018.10.011>

RCTs, although this may overlap with attitudes and considerations of patients in some of the studies.⁶⁻¹⁷

For these reasons, we investigated how STEMI patients undergoing primary PCI assessed their ability to decide participation in RCTs. We hypothesized that patients felt pressured to participate and had difficulty accepting participation if asked to enter more than one RCT.

Methods

Study design and setting

This was a questionnaire-based study conducted at the Department of Cardiology at Aalborg University Hospital, a tertiary referral hospital in the North Denmark Region, from March 2012 to November 2012. During this study period, our department had 4 running RCTs including DANAMI-3,¹⁸ SORT OUT VI,¹⁹ MITOCARE,²⁰ and GEVAMI,²¹ in which participation could potentially be asked.

Study population

Our study population consisted of consecutive patients admitted with STEMI undergoing primary PCI who were asked to participate in at least one RCT. We only included patients ≥ 18 years of age who could read and understand Danish because these inclusion criteria were required by all RCTs.

Recruitment and sample size estimate

During the 9-month study period, trained research nurses (authors P.B., A.H.A., M.B., and H.P.H.) approached patients. We asked 100 patients to participate in our study, which was needed to reach our sample size requirement of at least 80 respondents. This sample size estimate was calculated using Raosoft sample size calculator with a 95% confidence interval and a 5% error margin.

Data collection

Data were collected using a self-administered questionnaire. A pilot study of 10 patients was conducted to assess whether any questions required revision, and this was not necessary.

Questionnaires were distributed to patients 6 to 48 hours after primary PCI. This ensured that patients were still in-hospital and had as well participation in RCTs as the provided information on RCTs present in memory.

The questionnaire was divided into 2 sections. Section 1 included age, sex, agreement for participation in RCTs, and the number of RCTs that patients participated in. Section 2 assessed the following: level of understanding the actual RCT, level of opportunity to ask additional questions after the provided information, level of feeling pressured to participate, reasons for participation, and thoughts on future participation.

Some of the questions were closed-ended questions, meaning that patients could only answer “yes,” “no,” or

“do not know.” Other questions were open-ended, meaning that they could be answered on a scale ranging from 0 to 15 to give patients the opportunity of rating their experience.

Patients were anonymized and given a unique ID number for registration purposes during data collection and analysis.

Statistical analysis

Continuous variables were reported as mean (SD), and categorical variables as counts (%).

First, we stratified patients according to who accepted participation in RCTs, who did not accept participation, and who did not respond to the questionnaire. Between these groups, we tested for differences in age and sex as well as time, day, and month of admission with STEMI using independent *t* and χ^2 tests, as appropriate. A *P* value $< .05$ was considered statistically significant.

Second, we collapsed questions based on the 0-15 scale into 2 groups, with scores between 0 and 5 indicating “unacceptable level” and between 6 and 15 indicating “acceptable to satisfactory level.”

Data management and analysis were performed using Stata, version 15.0 (StataCorp, College Station, TX) and R, version 3.5.1 (R Core Team [2018]. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL: <https://www.R-project.org/>).

Ethics

The North Denmark Region Committee on Health Research Ethics was approached, and our study did not require approval according to the Danish Law of Questionnaires and Interviews. Because our study holds no personal data, registration by the Danish Data Protection Agency was not required. Our study conforms to principles outlined by the Declaration of Helsinki²²; thus, our study was explained in written and oral format to patients. By Danish law, this type of questionnaire-based studies did not require informed consent of patients.

Sources of funding


This study was funded using departmental funding sources only; thus no extramural funding was used to support this work. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.

Results

Patients and characteristics

Of all 100 consecutive STEMI patients undergoing primary PCI who were approached and asked to fill out the questionnaire in our study, 82 patients (82%) were

Figure 1



Consort diagram of all participating, nonparticipating, and nonresponding patients including their baseline characteristics.

male, and the remaining 18 patients (18%) were female. The mean (SD) age of patients was 61 (12) years. Most patients were asked to participate in RCTs during daytime hours and weekdays.

Participation

A total of 96 patients (of 100) answered the questionnaire yielding a response rate of 96%. However, not all patients answered all questions resulting in varying response rates across individual questions.

Although 94 patients (of 100; 94%) accepted inclusion in at least one RCT, 6 patients (of 100; 6%) declined participation. Overall, between the 90 patients participating, 6 not participating, and 4 not responding to the questionnaire, no differences in age ($P = .481$) and sex ($P = .399$) as well as time ($P = .531$), day ($P = .738$), and month ($P = .617$) of admission with STEMI were observed. A consort diagram of all participating, nonparticipating, and nonresponding patients including their baseline characteristics is depicted in Figure 1. The distribution of patients across individual RCTs is depicted in Figure 2.

When comparing patients' perception of the number of RCTs that they participated in with the actual registered number of RCTs, most patients believed that they participated in less RCTs than was actually the case, as depicted in Figure 3. In addition, 20 patients (of 100; 20%) reported that they did not know in which RCTs that they participated in.

Level of understanding

Patients were asked to rate their level of understanding the information provided on participation in RCTs using the 0-15 scale, as depicted in Figure 4. A total of 88 patients (of 96) answered the question, and 69 patients

(of 88; 78%) reported to understand the information at an acceptable to satisfactory level (score, 6-15; mean score, 11). In comparison, 19 patients (of 88; 22%) rated their level of understanding at an unacceptable level (score, 0-5; mean score, 2).

Of the 6 patients declining participation in any RCT, 1 patient did not answer, 3 patients rated their understanding at an unacceptable level (score, 0-5), and the remaining 2 patients rated their understanding at an acceptable to satisfactory level (score, 6-15).

Additional questions


Patients were asked to rate their level of opportunity to ask additional questions about participation in RCTs using the 0-15 scale. A total of 84 patients (of 96) answered the question, and 70 patients (of 84; 83%) rated their experience at an acceptable to satisfactory level (score, 6-15) and 14 patients (of 84; 17%) at an unacceptable level (score, 0-5).

Feeling pressured

Patients were asked to rate their level of feeling pressured to participate in RCTs and how this affected their decision-making process using the 0-15 scale. Overall, 2 patients (of 96; 2%) reported to have felt pressured, of which 1 patient refrained from rating how this affected the decision-making process, and the remaining patient rated 8, meaning that this did not affect the decision.


A total of 94 patients (of 96; 98%) reported that they did not feel pressured to participate in RCTs. Of these, 55 patients chose to rate their level and rated their experience between 7 and 15, with most ($n = 51$) rating higher than 11.

Figure 2




The distribution of patients across individual RCTs.

Figure 3




Comparison of patients' perception of the number of RCTs that they participated in with the actual registered number of RCTs.

Figure 4



The rated level of understanding the information about participation in RCTs of patients using the 0-15 scale.

Figure 5



Motivational factors of patients toward participation in RCTs.

Reasons for (non-)participation

Patients were asked to report one or more motivational factors for participation in RCTs, as depicted in Figure 5. The major reason for participation was “To help clinical research,” which 75 patients (of 90; 83%) reported.

The 6 patients declining participation in RCTs reported the following: “concerned about receiving an untested treatment” (n = 1), “do not wish to participate” (n = 1), “unable to manage the decision” (n = 3), “wish to discuss participation with relatives” (n = 1), “previous experience with clinical research” (n = 1), “felt pressured to participate” (n = 0), and “do not know” (n = 2).

Future participation

Patients were asked if they felt positive about future participation in RCTs. A total of 93 patients (of 100) reported the following: “yes” (n = 79; 85%), “no” (n = 3, 3%), and “do not know” (n = 11, 12%). Of these, the 6 patients declining participation in RCTs reported the following: “yes” (n = 4), “no” (n = 1), and “do not know” (n = 1).

Discussion

Our study revealed several valuable insights into attitudes and considerations of patients toward participation in RCTs during primary PCI for STEMI in Denmark. Our main finding was that 78% of patients reported an acceptable to satisfactory level of understanding the information provided on participation in RCTs, although only half correctly reported the actual registered number of RCTs that they participated in. Furthermore, patients did not feel pressured to participate and had the opportunity to ask additional questions during the

decision-making process. Notably, most patients participated to help clinical research and were positive about future participation in RCTs.

To our knowledge, only limited evidence is available on attitudes and considerations of STEMI patients undergoing primary PCI toward participation in RCTs. Instead, most studies have focused on how STEMI patients understand the informed consent process in RCTs.⁶⁻¹⁷ However, that selected Danish STEMI patients undergoing primary PCI in our study reported that they (a) had an acceptable to satisfactory level of understanding, (b) had the opportunity to ask additional questions, (c) did not feel pressured to participate, (d) wanted to help clinical research, and (e) were positive about future participation are all relevant findings underscoring the ethical justification of RCTs among STEMI patients.⁴ These findings generally corroborate a recent international survey observing that of 2,194 former clinical research participants, nearly 50% participated to help advance clinical research, 81% considered the informed consent form easy to understand, and most would participate again and would recommend participation to others.²³ Studies have further suggested that STEMI patients participating in RCTs compared with similar nonparticipating patients overall had the same outcomes, meaning that it is safe for STEMI patients to consent to RCTs without jeopardizing survival.^{24,25} Taken together, this further speaks to enhancing patient recruitment in STEMI RCTs as underparticipation remains a long-standing systemic challenge worldwide.³

Significant determinants of understanding the information provided on participation in RCTs among STEMI patients have been found to be the absence of pain at inclusion, high educational level, and male sex.¹³

Especially, pain and other symptoms experienced during STEMI have been found to explain why some patients consent to RCTs to rid themselves of pain and to receive treatment immediately.^{4,8,10,11,16,17} Our study revealed that the circumstances during primary PCI place high demands to physicians providing the information on RCTs, and how the specialized medical and nursing staff managing the patient during the emergency acts. As such, it remains crucial that patients understand and feel that participation in RCTs is completely voluntary.

Given the psychological distress of patients during the acute phase of STEMI and primary PCI, it is a challenge for physicians to thoroughly inform patients about RCTs. According to Ågård et al,⁷ 86% of physicians felt that STEMI patients were unable to understand all the information provided on participation in RCTs. However, in our study of selected STEMI patients undergoing primary PCI in Denmark, most patients (78%) reported to understand the information at an acceptable to satisfactory level. Taken together, this was interpreted as sufficient, as patients simultaneously felt that they had the opportunity to ask additional questions during the decision-making process. In previous studies, rates of understanding the information provided on RCTs to make a good decision have been reported to range from 52% to 88%.^{6,9,10,12-17} In contrast, the corresponding rate in nonemergency cardiovascular RCTs has been reported to be as high as 90%.²⁶

That only 2% of patients in our study reported to have felt pressured to participate in RCTs during the acute phase of STEMI and primary PCI did not match our hypothesis, as we initially believed that most patients would feel obliged to participate. Accordingly, this is rather reflected by the fact that 83% of patients in our study participated to help clinical research, and 85% would be willing to participate in future RCTs. These response rates are generally comparable with those of previous studies.^{9,10,12,15,16} In addition, because none of the patients commented on the number of RCTs that they participated in, it did not seem that this was of significant importance to patients.

Despite promising, our findings should be considered in the light of various limitations. The findings may have been different in other countries owing to cultural and social differences. The varying response rates across individual questions may raise the possibility of selection bias, as it is likely that returned questionnaires were from patients with more extreme experiences, both favorable and otherwise, or those interested in clinical research. Our study was conducted among STEMI patients asked to be included in at least one RCT during primary PCI, and it is possible that the study staff screened only patients that they felt would accept participation rather than all patients meeting RCT criteria. In addition, the findings may be different in studies involving more chronically stable patients who are

usually outpatients and may consider participation in RCTs over days to weeks rather than minutes as STEMI patients have to.

Conclusions

Danish STEMI patients seemed to have positive attitudes and considerations toward participation in RCTs despite their acute medical condition and the emergency environment. The overall self-assessed ability of patients to make a decision about participation in RCTs was good, not influenced by pressure or misunderstanding of information, and driven by the fact that patients wanted to help clinical research and would be willing to participate in future RCTs.

Acknowledgments

We would like to thank patients who participated in our study and their relatives. We further gratefully acknowledge the generous assistance and help provided to us by the staff at the Department of Cardiology at Aalborg University Hospital, Aalborg, Denmark. Finally, we would like to thank the statistical staff at Aalborg University Hospital, Aalborg, Denmark for support.

References

1. Thomas MP, Bates ER. Update on primary PCI for patients with STEMI. *Trends Cardiovasc Med* 2017;27(2):95-102.
2. Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *J Am Coll Cardiol* 2016;67(10):1235-50.
3. Martin SS, Ou FS, Newby LK, et al. Patient- and trial-specific barriers to participation in cardiovascular randomized clinical trials. *J Am Coll Cardiol* 2013;61(7):762-9.
4. Dickert NW, Miller FG. Involving patients in enrolment decisions for acute myocardial infarction trials. *BMJ* 2015;351:h3791.
5. von Känel R, Hari R, Schmid JP, et al. Distress related to myocardial infarction and cardiovascular outcome: a retrospective observational study. *BMC Psychiatry* 2011;11:98.
6. Dickert NW, Fehr AE, Llanos A, et al. Patients' views of consent for research enrollment during acute myocardial infarction. *Acute Card Care* 2015;17(1):1-4.
7. Ågård A, Herlitz J, Hermerén G. Obtaining informed consent from patients in the early phase of acute myocardial infarction: physicians' experiences and attitudes. *Heart* 2004;90(2):208-10.
8. Gammelgaard A, Rossel P, Mortensen OS. Patients' perceptions of informed consent in acute myocardial infarction research: a Danish study. *Soc Sci Med* 2004;58(11):2313-24.
9. Gammelgaard A, Mortensen OS, Rossel P. Patients' perceptions of informed consent in acute myocardial infarction research: a questionnaire based survey of the consent process in the DANAMI-2 trial. *Heart* 2004;90(10):1124-8.
10. Williams BF, French JK, White HD. Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent

- substudy): a prospective observational study. *Lancet* 2003;361(9361):918-22.
11. Ågård A, Hermerén G, Herlitz J. Patients' experiences of intervention trials on the treatment of myocardial infarction: is it time to adjust the informed consent procedure to the patient's capacity? *Heart* 2001;86(6):632-7.
 12. Yuval R, Halon DA, Merdler A, et al. Patient comprehension and reaction to participating in a double-blind randomized clinical trial (ISIS-4) in acute myocardial infarction. *Arch Intern Med* 2000;160(8):1142-6.
 13. Kucia AM, Horowitz JD. Is informed consent to clinical trials an "upside selective" process in acute coronary syndromes? *Am Heart J* 2000;140(1):94-7.
 14. Smithline HA, Mader TJ, Crenshaw BJ. Do patients with acute medical conditions have the capacity to give informed consent for emergency medicine research? *Acad Emerg Med* 1999;6(8):776-80.
 15. Williams BF, French JK, White HD. Is our method of obtaining consent appropriate for randomised controlled trials in acute myocardial infarction? *N Z Med J* 1997;110(1049):298-9.
 16. Ockene IS, Miner J, Shannon TA, et al. The consent process in the Thrombolysis in Myocardial Infarction (TIMI—phase I) trial. *Clin Res* 1991;39(1):13-7.
 17. Smith HL. Myocardial infarction—case studies of ethics in the consent situation. *Soc Sci Med* 1974;8(7):399-404.
 18. Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. *Lancet* 2015;386(9994):665-71.
 19. Raungaard B, Jensen LO, Tilsted HH, et al. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. *Lancet* 2015;385(9977):1527-35.
 20. Atar D, Arheden H, Berdeaux A, et al. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. *Eur Heart J* 2015;36(2):112-9.
 21. Jabbari R, Engstrøm T, Glinge C, et al. Incidence and risk factors of ventricular fibrillation before primary angioplasty in patients with first ST-elevation myocardial infarction: a nationwide study in Denmark. *J Am Heart Assoc* 2015;4(1), e001399.
 22. Rickham PP. Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. *Br Med J* 1964;2(5402):177.
 23. The Center for Information and Study on Clinical Research Participation (CISCRP). 2017 Perceptions & insights study: report on the participation experience. Available from: <https://www.ciscrp.org/download/2017-perceptions-insights-study-the-participation-experience/?wpdmdl=8770>. Accessed November 27, 2018.
 24. Juliard JM, Golmard JL, Feldman LJ, et al. Impact of participation in randomized trials of reperfusion therapy on the time to reperfusion and hospital mortality in ST-segment elevation myocardial infarction: a single-centre cohort study. *Eur Heart J Acute Cardiovasc Care* 2016;5(2):193-7.
 25. Vist GE, Bryant D, Somerville L, et al. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. *Cochrane Database Syst Rev* 2008;3, MR000009.
 26. Sugarman J, Kass NE, Goodman SN, et al. What patients say about medical research. *IRB* 1998;20(4):1-7.